神经内分泌肿瘤药物临床试验进展. (Chinese)

Neuroendocrine neoplasm (NEN) is a group of heterogeneous malignancies arising from neuroendocrine cells and peptidergic neurons. According to its cell differentiation, NEN can be divided into two distinct groups as well-differentiated neuroendocrine tumor (NET) and poorly-differentiated neuroendocrine carcinoma (NEC). For advanced NEN, medication is the preferred treatment. In this article, we reviewed current clinical trials in medical treatment for NEN and aimed to provide treatment reference in clinical practice. [ABSTRACT FROM AUTHOR]

神经内分泌肿瘤 (neuroendocrine neoplasm, NEN) 是一类起源于神经内分泌细胞及肽能神经元的高度异质性的 少见肿瘤。根据细胞分化的程度, NEN可分为分化好的神经内分泌瘤 (neuroendocrine tumor, NET) 和分化差的神经内分 泌癌 (neuroendocrine carcinoma, NEC) 。药物治疗是进展期NEN患者首选的全身治疗方式。本文总结了近年来在NEN领 域的重要药物临床试验进展, 为临床治疗提供参考。 [ABSTRACT FROM AUTHOR]

Copyright of China Oncology is the property of Editorial Board of China Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)